CATEGORIES: Clinical Trials | Research

Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT) Calling CMT1A Patients Ages 18-75

by | Sep 1, 2020 | 2 comments

This study is a new international research project funded by the National Institutes of Health (NIH) called Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT). Dr. David Herrmann at the University of Rochester is the study’s Principal Investigator. There are 3 participating centers in the USA. 

※ University of Rochester, NY (Dr. David Herrmann, shown in photo below) 

※ University of Pennsylvania, PA (Dr. Steve Scherer) recruitment completed

※ University of Iowa, IA (Dr. Mike Shy) 

This study is enrolling people with CMT1A who are aged 18-75. 

The purpose of this study is to determine the best way to measure the progression of Charcot-Marie-Tooth Disease Type 1A (CMT1A) over time. This study is important to help us to prepare for clinical trials. We are looking at new ways of measuring changes in CMT1A progression over a short period of time and assessing their usefulness in measuring effects of treatments in future clinical trials.  In addition to measurements that are currently used to measure progression of CMT1A such as strength and sensation, this study would also include the following: 

※ Two questionnaires (the CMT Health Index and Overall Neuropathy Limitation Scale) that explore how you think CMT1A affects you

※ CMT Functional Outcome Measure (CMT-FOM) which assesses balance, walking, standing up from sitting in a chair, and manual dexterity 

※ We will also test your ability to feel nylon monofilaments (like fishing line) and photographing a small area of your hand using a non-invasive microscope that can look into the skin and see nerve endings 

※ Nerve conduction studies on one arm and one leg 

※ For some participants, an MRI scan of your lower leg muscles The study visits are approximately 4 hours (with an additional hour for optional MRI). 

The study visits are at 6-12 month intervals for up to 3 years. Participants will receive an honorarium and reimbursement of qualified travel expenses.  For more information about participating, please contact:   

University of Rochester 

Steffen Behrens-Spraggins (585) 275-5760   

University of Iowa 

Alexa Bacha (319) 467-5006 

[email protected]

Learn more on this topic

Related Blog Posts

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

HNF-WVU-NIOSH Study update:

We are pleased to update our readers on the progress of the WVU-NIOSH study, “A Bi-Directional Translational Model of Exercise Training in the Treatment of Charcot-Marie-Tooth Disease”

Dr. Robert Baloh Answers Our Questions About iPS Cell Research

Big news is happening on a cellular level at Cedars-Sinai Medical Center’s Regenerative Medicine Institute in Los Angeles, CA.  Robert H. Baloh, MD PhD, Director of Neuromuscular Medicine, in conjunction with Patrick D. Lyden, MD Neurology Dept. Chair, and Clive Svendsen, PhD, Institute Director, are studying disorders that start in nerve cells. 

Join the conversation

Leave a Comment


  1. Dr. Roberta DeLuca

    My husband has CMT. I was totally unaware there was a community! We live in Central California and could be interested in some help or studies.

  2. Roxanne

    HI there.
    Are there any clinical trials or research centres in South Africa.


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news